Targovax announces Notice of Allowance in the US on patent covering the TG mutant-RAS neoantigen vaccine platform

Further strengthening the IP protection of the TG platform

Oslo, 8 March 2019: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance on the patent application No. 15/461837. The allowed patent protects the composition of matter of Targovax’s mutant-RAS specific neoantigen peptides and vaccines TG02 and TG03.

Jon Amund Eriksen, special advisor and Co-founder of Targovax, said: “We are delighted that this US patent has been allowed, further strengthening Targovax’s intellectual property portfolio covering the very important mutant-RAS neoantigen peptide platform. The oncology market is ever expanding, with the immuno-oncology segment expected to see the largest growth in the coming years. Securing this patent protects our innovative mutant-RAS specific cancer immunotherapy platform and strengthens our market position in the US for treatment of RAS-mutated cancers.”

Targovax’s proprietary mutant-RAS neoantigen vaccine platform is designed to treat patients with tumors harboring RAS mutations. Mutations in the RAS genes are a driving cause of cancer development and progression and is linked to poor prognosis. By inducing an anti-mutant-RAS specific immune response, TG vaccines have the potential to delay disease progression and increase survival, with a favorable safety profile.

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media and IR enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no